Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell

The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL).  

This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients led to durable remissions.  

Some background

CAR T-cell therapy is a type of immunotherapy approved in the US for treating certain types of blood cancers. It involves changing T cells (a type of immune cell) in the lab so they would attack and kill cancer cells. In patients with CLL who achieve complete remission (CR) with CAR T-cells, remissions are very durable.   

Ibrutinib is a type of targeted therapy called a tyrosine kinase inhibitor (TKI). It blocks a protein on CLL cells that stops the growth and spread of CLL. Data from experimental studies suggested that CART-19 and ibrutinib may be more effective when combined in patients with CLL. Therefore, it is important to evaluate whether adding CART-19 to ibrutinib treatment would be safe and effective in patients with CLL.  

Methods & findings

This study involved 19 patients with CLL on ibrutinib treatment. Patients were not in CR despite at least 6 months of ibrutinib therapy. All patients received autologous antiCD19 humanized binding domain T cells (huCART-19). The average follow-up time was 42 months.  

18 patients developed cytokine release syndrome (CRS) and 5 patients developed neurotoxicity. CRS is a collection of symptoms that can develop as a side effect of immunotherapy. It involves a large number of immune cells released into the blood. Symptoms include fever, headache, or nausea. Neurotoxicity involves a disruption in the regular activity of the nervous system.  

At 12 months, 72% of patients had no measurable residual disease (MRD). 

The estimated overall survival (OS) rate at 48 months was 84%. The estimated survival rate without cancer worsening at 48 months was 70%.  

Of 15 patients with undetectable MRD at 3 or 6 months, 13 remained in ongoing CR at the last follow-up. 

The bottom line

This study concluded that in patients with CLL not achieving a CR despite at least 6 months of ibrutinib, adding huCART-19 led to a high rate of deep and durable remissions. 

The fine print

This study had a small number of participants. This study was funded by Novartis, the manufacturer of CART-19.

Published By :

Blood advances

Date :

Mar 29, 2022

Original Title :

Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia.

click here to get personalized updates